Nosocomial and Ventilator-associated Pneumonia

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pulmonology

Background:

• Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), significantly increases patient morbidity, mortality, and healthcare costs.
• Management is complicated by the rise of multidrug-resistant organisms (MDROs).

Purpose of the Study:

• To provide a comprehensive review of the epidemiology, pathophysiology, and management of NP and VAP.
• To focus on the challenges posed by MDROs and guide clinical decision-making.

Main Methods:

• Synthesis of current evidence through a question-and-answer format.
• Critical appraisal of international guidelines (IDSA/ATS, ERS, SEPAR).
• Review of diagnostic tools, novel antimicrobials, and treatment duration strategies.

Main Results:

• Risk factors for MDROs include prolonged ventilation and prior antibiotic exposure, necessitating risk stratification.
• Rapid molecular diagnostics can improve yield and antimicrobial stewardship.
• A 7-8 day antibiotic course is generally recommended, with procalcitonin aiding discontinuation decisions.

Conclusions:

• Effective management of NP/VAP requires understanding MDRO risk factors and leveraging diagnostic tools.
• Optimizing antimicrobial selection and duration is crucial in the era of resistance.
• This review serves as an evidence-based reference for clinicians managing complex cases.